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Abstract
It was shown previously that an ankyrin-sensitive, phosphatidylethanolamine/phosphatidylcholine (PE/PC) binding site
maps to the N-terminal part of the ankyrin-binding domain of b-spectrin (ankBDn). Here we have identified the amino acid
residues within this domain which are responsible for recognizing monolayers and bilayers composed of PE/PC mixtures. In
vitro binding studies revealed that a quadruple mutant with substituted hydrophobic residues W1771, L1775, M1778 and
W1779 not only failed to effectively bind PE/PC, but its residual PE/PC-binding activity was insensitive to inhibition with
ankyrin. Structure prediction and analysis, supported by in vitro experiments, suggests that ‘‘opening’’ of the coiled-coil
structure underlies the mechanism of this interaction. Experiments on red blood cells and HeLa cells supported the
conclusions derived from the model and in vitro lipid-protein interaction results, and showed the potential physiological
role of this binding. We postulate that direct interactions between spectrin ankBDn and PE-rich domains play an important
role in stabilizing the structure of the spectrin-based membrane skeleton.
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Introduction
The shape and deformability of erythrocytes are maintained by
the presence of the membrane skeleton, which associates with the
plasma membrane through a combination of protein-protein and
protein-lipid interactions. The main player in formation of this
network is spectrin, which attaches to the plasma membrane
primarily through ankyrin and other binding partners [1,2,3,4,5].
In addition, the ability of spectrin to bind to phospholipids of the
membrane inner leaflet remains of considerable interest. Studies of
spectrin-lipid interactions, dating from the early nineteen seven-
ties, have revealed that spectrin repeats possess lipid-binding
properties [6]. Several binding sites for phosphatidylserine (PS)-
rich domains are evident on both a- and b-spectrin subunits, and
supporting roles for these sites in spectrin-4.1R protein and
spectrin-ankyrin binding have been suggested [7,8,9,10,11]. The
importance of PS asymmetry for maintaining the mechanical
properties of the erythrocyte membrane was documented by
Manno et al. [12]. Apart from its PS-binding ability, spectrin also
binds to PE-rich domains, as shown by others [13] and by us
[14,15]. The PE lipid-binding site was found to be located within
the ankyrin-binding domain (ankBDn), encompassing the 14th
and 15th segment [16] of b-spectrin and situated within the
N-terminal 38 amino acid residues of this domain [17,18]. We
showed previously that binding of erythroid spectrin to PE/PC
mixtures, both phospholipid vesicles and monolayers, was
competitively inhibited by ankyrin, a feature that was only limited
in the case of PS binding by erythroid spectrin [14]. This suggested
the possibility of a regulatory mechanism based on inhibition of
spectrin-PE binding by ankyrin.
Further structural studies using site-directed spin labeling
technique suggested the presence of a possible hydrophobic
surface that could be responsible for the interaction with lipids
[19]. The recently published structure of the ankyrin-binding
domain and its complex with ankyrin revealed that the putative
lipid-binding site would be buried inside the coiled-coil structure
and a major structural rearrangement of the triple helical bundle
would be needed for its exposure [20,21]. Indeed, as was reported
by Czogalla et al. [22] during the interactions of ankBDn with PE/
PC liposomes some structural changes in the mutual alignment of
the helices were observed and an ‘‘opening’’ of the structure was
proposed.
The present study aimed to further explore the possibility that
the previously proposed hydrophobic patch is the main site for
interactions with PE. To address this issue we constructed a series
of point mutations inside the lipid-binding part of the ankyrin-
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associations of these mutants with PE/PC mono- and bilayers.
Our results indicate that residues W1771, L1775, M1778 and
W1779 are directly responsible for lipid-binding activity within the
ankyrin-binding domain of erythroid b-spectrin. On the basis of
structural data reported by us [22] and others [20,21] as well as
our biochemical analyses we provide a consistent model of this
interaction and possibly its inhibition by ankyrin. Furthermore, we
present data obtained from studies on resealed erythrocyte ghosts
and HeLa cells that show morphological changes dependent on
the presence of the intact, mutation-free, N-terminal lipid-binding
site within the ankyrin-binding domain of b-spectrin.
Considering that both PE and PS are asymmetrically distributed
in the membrane and that erythrocyte membrane holds more PE
than PS [23], the ability of spectrin to interact with PE in an
ankyrin-dependent manner could be physiologically important. It
has been shown that a normal spectrin skeleton is present in
ankyrin-deficient mouse erythrocytes, demonstrating the potential
of spectrin to form stable attachment sites to the plasma
membrane [24]. As suggested previously by Sikorski and
Białkowska [25], the major attachment site would be the PE-
binding domain. Here we provide further evidence that the lipid-
binding feature of ankBDn is of functional importance, based on
observations of GFP-tagged ankBDn and its mutants in cells.
Results
Expression, purification and characterization of the
ankyrin-binding domain of b-spectrin and its mutants
Our previous results indicated that the ankyrin-sensitive PE/
PC-binding site of b-spectrin was limited to the 38 amino acid
residues in the N-terminal fragment of the 14C helix of the
ankyrin-binding domain [18]. Figure 1A shows this fragment and
its placement in the helical context of ankBDn. The localization of
these residues as presented in this figure suggests the formation of a
hydrophobic patch, which is consistent with the data obtained by
Czogalla et al. [19,22]. Below we describe experiments to identify
amino acid residues crucial for binding PE/PC mono- and
bilayers. We constructed a series of mutants that contained
substitutions in the region of residues 1771–1779 (mutants are
named for the mutated residues they contain) and 1782–1786
(names starting as Mut...), as these are the most hydrophobic
regions in the N-terminal fragment of the helix 14C of the ankyrin-
binding domain (1768–1805). The primary intent of these
substitutions was to reduce the exposed hydrophobic surface of
this region of spectrin in order to test whether this was key to
ankBDn-lipid interactions. We also avoided creating ‘‘patches’’ of
serine residues; therefore, in some mutants, W1779 was substituted
by alanine. The difference in the hydrophobicity index of S and A
Figure 1. Models of ankyrin-binding domain. A) Ankyrin-binding domain, with residues W1771, L1775, M1778, W1779 marked in green. Helix
14A is shown in red, helix 14B is colored orange. B) Hydrophobicity analysis of a 38 amino acid fragment of ankyrin-binding domain (ankBDn) and its
mutant (SSSA) by 3D-mol software. Colors represent hydrophobicity of amino acid residues: deep red, hydrophobic; and deep blue, hydrophilic.
Arrows indicate exchanged residues.
doi:10.1371/journal.pone.0021538.g001
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affected the hydrophobicity parameters [26] of the protein (Fig. 1B)
but, as observed by the CD spectra (examples are shown in
Fig. 2B,C), had little effect on the secondary structure of the
domain in terms of either the helical structure content at 10uCo r
the melting temperature. This indicates that the observed changes
in binding activities of the mutants stem from local and not global
structural changes.
PE/PC-monolayer binding activity of ankBDn and its
mutants
For basic characterization of full-length ankBDn and its mutants
we used a monolayer assay, which provides a convenient tool for
the detection of protein-lipid interactions, as changes in the surface
pressure indicate differences in the level of interactions between a
protein and the lipid monolayer. In our experiments we used a
‘‘loose’’ monolayer of PE/PC at a 3:2 (w/w) ratio at initial surface
pressures of 8–12 mN/m [27]. Although it is far from the 30–
35 mN/m pressures typical for natural membranes, these
conditions give important indications for lipid-protein interaction,
as was previously shown [18,28,29]. The combined results are
shown in Figure 3A. The plateau levels of Dp for the mutants were
normalized using the level of wild-type ankBDn (2–3 mN/m) as
100%. Also shown are the sequences of the N-terminal 38 residues
of wild-type ankBDn and the mutants.
The first of these mutants to be tested was WLSA, which was a
double mutation M1778S/W1779A (see Fig. S1A). The mono-
layer assay showed that WLSA protein retained ,75% of its lipid-
binding ability as compared to ankBDn, suggesting that the major
contribution to lipid binding was located more to the N- or C-
terminus of the WLSA mutant. To address the latter possibility, we
generated three mutants, called ‘‘Mut…’’ to underline the fact that
they contained substitutions within the hydrophobic stretch of
residues located in the middle of the 38-residue lipid-binding
region of ankBDn: MutSSK, L1782S/L1785S/I1786K; MutSSD,
L1782S/L1785S/I1786D; and MutSSS, L1782S/L1785S/
I1786S (Fig. S1B). The results indicated that these three mutant
proteins had the same lipid-binding capacity as the wild-type
protein (Fig. 3A).
To investigate the key lipid-binding determinants on the N-
terminal portion of the ankBDn we created WSSA, which contained
the three mutations L1775S/M1778S/W1779A (Fig. S1C), and
SSSA, which was a quadruple mutant,W1771S/L1775S/M1778S/
W1779A (Fig. 1B). Both of these mutants exhibited decreased lipid-
binding activity in the monolayer assay, and the decrease was
dependent on the number of mutations. WSSA retained 60–75% of
lipid-binding activity, while SSSA, the quadruple mutant, retained
only 20% of lipid-binding activity as compared to ankBDn. To
specifically assess the role of tryptophan residues, a second triple
mutant, SSSW, W1771S/L1775S/M1778S (Fig. S1D) was con-
structed. As measured in the monolayer system, the observed
decrease in Dp was comparable for both mutants, reaching ,65–
75%. A final triple mutant, CLSC, W1771C/M1778S/W1779C
(Fig. S1E), was constructed with the intent to test how PE/PC
binding would be affected when the bulky tryptophan residues
(W1771 and W1779) were exchanged with smaller, but basically
hydrophobic cysteines. It was found that CLSC behaved compara-
bly to the other triple mutants tested. The lipid-binding ability was
retained at the level of 60–70%, as measured by the plateau level in
the monolayer assay.
Finally the last of our constructs was ‘‘Ala8’’ in which the 8
amino acid residues (residues 1768–1775) were substituted by
alanine to confirm our previous data obtained from truncated
mutants [18]. This substitution should not compromise the helical
structure of this part of the polypeptide chain as alanine residues
prefer an a-helical arrangement and should mimic well the N-
terminal 8 residue deletion mutant [18]. In the case of this mutant
(1768–1775A, see Fig. S1F), its ability to affect the PE/PC
monolayer surface pressure was decreased by more than 50% as
compared to wild-type ankBDn (Fig. 3A), indicating that, although
significantly lowered, the ability of Ala8 to interact with PE/PC
monolayers was retained. We interpret the data shown in Fig. 3 to
indicate that lipid binding is largely mediated by residues within
the first 12 amino acids of ankBDn.
In addition to binding PE, spectrin also binds to PS [9],
although with less sensitivity to ankyrin. Consequently, we also
measured interactions of ankBDn and the SSSA mutant with PS/
PC monolayers. The results presented in the Figure 3B indicate
that while the PS-binding ability of wild-type ankBDn is very
similar to that observed for PE/PC monolayers, the SSSA mutant
retains ,50% PS/PC binding compared to the abovementioned
,20% of PE/PC monolayer binding. The difference is not
unexpected as positively charged residues which are present within
the studied region (for example K1772) probably contribute to PS-
binding activity [30]. It seems sufficient to quench PE binding just
by substitution of the hydrophobic residues. The positively
charged residues may still stabilize PS-binding activity of this site.
Figure 2. Purity and secondary structure of wild-type and
mutant protein. A) Purified proteins. Electrophoresis was carried out
in 10% polyacrylamide gel in the presence of 0.1% SDS. Gels were
stained with Coomassie Blue. Arrow indicates ,42 kDa molecular mass.
B) Melting curves of proteins shown in B). The Tm was determined by
second derivative calculation. C) CD spectra of recombinant ankyrin-
binding domain (ankBDn) and quadruple mutant SSSA at 20uC. Inset:
comparison of a-helix content calculated from CD spectra obtained at
indicated temperature.
doi:10.1371/journal.pone.0021538.g002
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ankBDn and its mutants
The monolayer technique is useful for screening for lipid-binding
properties of proteins but the data it provides are unsatisfactory for
obtaining the kinetic parameters of the interaction. To further
address the role of substituted residues in the lipid-binding process,
and to acquire kinetic data concerning these interactions,we carried
out several assays, including a pelleting assay, FRET-based assay,
and EIA. As expected from the monolayer experiments, the lowest
affinity for PE/PC vesicles seen in the FRET-based assay was
observed for the SSSA mutant (KD.5 mM). The calculated KD of
the SSSA mutant was increased at least 10-fold compared to
ankBDn (KD=0.3160.07 mM; 6SE) (Fig. 4A). The double
mutant, WLSA, exhibited moderate affinity toward liposomes, as
the measured equilibrium dissociation constant was in the
submicromolar range (0.7160.34 mM; 6SE). The triple mutants
SSSW (KD.2 mM), WSSA (KD=1.160.24 mM; 6SE), and CLSC
(KD.1 mM) exhibited significant decreases in affinity towards PE/
PC liposomes. Also, the KD for Ala8 was several-fold higher than
the KD for ankBDn, confirming our observation from the
monolayer assay that the major contribution to lipid binding in
ankBDn comes from the hydrophobic patch within the first 12 N-
terminal amino acid residues. We also performed experiments with
a shorterversionofankBDnwithanintactputative lipidbindingsite
(ankBDnD1638–1767).The obtaineddissociationconstant valuefor
this protein (KD=0.5360.06 mM; 6SE) was similar to that of
Figure 3. Interaction of recombinant ankyrin-binding domain (ankBDn) and its mutants with PE/PC lipid monolayer. A) Interaction of
ankBDn and its mutants with PE/PC 3:2 (w/w) monolayer. The first 38 amino acid residues of ankBDn are shown; substitutions are marked in red. The
ankBDn plateau level is defined as 100% PE/PC binding activity and is equal to ,2.5 mN/m. Plateau levels were obtained at a protein concentration
of ,25–35 nM. Higher plateau levels indicate increased penetration of the lipid monolayer by protein. Average values were calculated from at least
three measurements. Significant differences from the plateau value obtained for wild-type ankBDn are marked (Student’s t test): * p,0.05;
** p,0.0001. Details in ‘‘Materials and Methods’’. B) Interaction of ankBDn and its quadruple mutant SSSA with PS/PC 3:2 (w/w) monolayer.
Interaction of ankBDn with PE/PC monolayer was defined as 100%.
doi:10.1371/journal.pone.0021538.g003
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localized on helix 14C.
A second quantitative approach was undertaken to cross-check
the above observations. EIA was performed as a modified ELISA
assay, which allows testing of the binding of unlabeled proteins to
immobilized liposomes (for details see Materials and Methods)
(Fig. 4B and Table 1). The values calculated for ankBDn and the
mutants show significant consistency with the measurements
presented above, with only slight variation for the SSSW and
WSSA triple mutants (Fig. 4B). As can also be seen, the
measurements obtained by this method strengthen the observation
that the quadruple mutation in SSSA leads to almost complete loss
of binding to PE/PC vesicles. We also performed a pelleting assay
with maleimide rhodamine labeled proteins and FAT PE/PC
liposomes. The data (Fig. S2 and Table 1) show significant
differences in the affinity of ankBDn and mutants of ankBDn for
PE/PC liposomes. The SSSA mutant failed to reach saturation
over the range of concentrations studied. The difference between
binding curves of SSSA occurring in FRET versus pelleting assays
could be due to extensive low-affinity, nonspecific binding of SSSA
protein to FAT liposomes. In conclusion, the data from the
quantitative binding assays demonstrated that mutants having at
least one of the native amino acid residues W1771, L1775,
M1778, or W1779 retained some lipid-binding activity compared
to the quadruple mutant, SSSA.
Competition between recombinant proteins and native
spectrin for liposome binding
To determine whether the introduced mutations would affect
the ability of ankBDn to compete for lipids with purified
erythrocyte spectrin, the binding of fluorescently labeled spectrin
by phospholipid vesicles in the presence of recombinant ankBDn
or its mutants, SSSW, SSSA, and CLSC, was carried out. The
wild-type recombinant ankBDn effectively inhibited binding of
labeled spectrin (50 nM) to PE/PC liposomes, but the SSSW and
SSSA mutants of ankBDn were poor competitors (Fig. 5A). The
CLSC mutant also failed to effectively compete with native
spectrin for liposome binding, although it exhibited a level of
competition slightly higher than that of the ‘‘serine’’ mutants. As a
control, unlabeled spectrin was used as the inhibitor. An effective
Figure 4. FRET-based assay (A) and EIA-based assay (B) for PE/PC binding of ankBDn and its mutants. A) Differences in binding affinity
of ankBDn and its mutant shown by FRET-based assay. FRET between TRITC-labeled proteins and PE/PC liposomes containing NBD-PE was detected
as a decrease in NBD-lipid fluorescence emission intensity upon protein binding to the liposomes. As a control of nonspecific binding, TRITC-labeled
IgG was used. Average values were calculated from at least three independent experiments. Error bars indicate standard deviation. B): Binding of
recombinant proteins by PE/PC liposomes. EIA assay: a multi-well plate was coated with PE/PC liposomes and incubated with the indicated proteins.
Anti-His-Tag antibodies were used for protein detection and anti-mouse-STAG antibodies were used for electrochemiluminescence reaction.
Thermally denatured ankBDn was used as a negative control. Average values calculated from at least three independent experiments. Error bars
indicate standard deviation.
doi:10.1371/journal.pone.0021538.g004
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unlabeled spectrin, was observed when the concentration of
labeled spectrin was 50 nM (data not shown).
These results show that recombinant ankBDn bound liposomes
and effectively competed with purified unmodified erythroidspectrin.
Introducing mutations in the N-terminal fragment of ankBDn
abolished this ability.
Ankyrin (ankSBD) specifically disrupts interaction of
ankBDn with PE/PC lipid surfaces
To test whether the residual PE/PC-binding activity of the
ankBDn mutants was sensitive to ankyrin, we performed inhibition
experiments based on the monolayer assay. We used the same
panel of mutants presented above, and instead of native ankyrin,
we used the fully active, recombinant spectrin-binding domain of
erythrocyte ankyrin (ankSBD) [31]. PE/PC-ankBDn binding
showed strong sensitivity to inhibition by ankSBD (Fig. 5B). The
triple mutants SSSW and CLSC exhibited decreased sensitivity to
inhibition by ankSBD. The residual PE/PC-binding activity of the
SSSA mutant failed to show any significant sensitivity to ankyrin
(Fig. 5B). KI values for ankBDn, CLSC and SSSW proteins were
0.15, 0.17, and 0.2 nM, respectively (it was not possible to
calculate a KI for SSSA). Because the residual PE/PC-binding
activity of the quadruple mutant (SSSA) was insensitive to
inhibition by ankSBD, this binding is probably not determined
by the hydrophobic patch within the first 12 residues.
These results suggested that the hydrophobic patch within the
N-terminal 12 amino acid residues of ankBDn was also involved in
the binding of ankyrin. This is consistent with the data of others
[20,21] suggesting the involvement of residues E1770, D1773,
E1777, D1781 in binding of ankyrin. Therefore, mutations in this
region might affect ankyrin binding. To address this issue we
measured the binding of ankBDn and its mutants to ankSBD using
EIA. We found that the binding curves and KD values were similar
for all studied proteins (, 27–55 nM), ruling out the possibility
that the lipid-binding region of ankBDn plays a crucial role in
ankyrin binding (Fig. 5C). This result indicates that the
conformation of the protein constructs was close to the native
form as they retained ankyrin-binding activity.
Ankyrin inhibits opening of the coiled-coil structure of
ankBDn, preventing its interaction with lipids
Ankyrin sensitivity is the main feature of ankBDn-PE/PC
interactions, yet its molecular mechanism remains unknown. Crystal-
lographic data regarding a complex of spectrin-ankyrin fragments
suggest that the binding site for ankyrin is located on helices 14A and
14C of spectrin [20,21,32,33]. In this work we postulate that
interaction between ankBDn and lipids is based on exposure of the
lipid-binding site located on helix 14C, which requires movement of
helix 14A. As ankyrin may bind to both helices, it may block their
movement upon lipid binding. To check this hypothesis we performed
inhibition experiments in which we used, besides ankBDn and SSSA
mutant, ankBDnD1638–1767 protein. This peptide lacks helices 14A/
B, yet is fully active in lipid and ankyrin binding, as shown here (Fig. 4,
Fig. 5C) and in our previous work [18,34].
The obtained results confirmed that lipid binding of ankBDn is
highly sensitive to inhibition by ankyrin as it is decreased by
,60%, as shown by sedimentation and EIA assays (Fig. 5D, 5E).
What is interesting, however, the lipid-binding property of
ankBDnD1638–1767 protein was only slightly affected by ankyrin.
These results, although somewhat different from those obtained
previously [18], suggest that the majority of the ankyrin inhibitory
effect probably stems from blocking of the movement of helix 14A,
which prevents exposure of the lipid-binding site.
This hypothesis is supported by the model of ankBDn upon lipid
binding (Fig. 6), which suggests that helix 14A movement uncovers
amino acid residues engaged in lipid binding. This model also
explains the mechanism of inhibition by ankyrin, as residues that
take part in interaction with ankyrin are located on both 14A and
14C helices (Fig. 6A, 6B). Ankyrin binds to both helices,
preventing their separation, and in consequence inhibits interac-
tion with lipids.
Effects of ankBDn and its mutants on morphology of
resealed erythrocyte ghosts
Spectrin-based membrane skeleton is particularly important in
erythrocytes as they lack other skeletal/scaffold structures. In the
work of Chorzalska et al. [35] it was shown that wild-type ankBDn
caused changes in the morphology and membrane properties of
erythrocyte ghosts. We decided to check what effect, in
comparison to the effect caused by ankBDn, mutants of ankBDn
that partially (CLSC) or completely (SSSA) lack lipid-binding
ability would have on erythrocyte ghosts.
Ghosts resealed in the presence of ankBDn exhibited enormous
deformations, whereas ghosts resealed in the presence of the CLSC
mutant of ankBDn exhibited formation of echinocytes (Fig. 7). An
interesting, although not unexpected, observation was a lack of
morphological changesin ghostsresealed in the presenceof the SSSA
Table 1. Summary of dissociation constants (KD) and Bmax values of the interaction of the recombinant ankyrin-binding domain
and its mutants with PE/PC liposomes obtained from the FRET-based analysis (Fig. 4A), EIA (Fig. 4B), and pelleting assays (Fig. S2).
FRET analysis EIA Pelleting assay
Protein KD [mM] ±SE Bmax±SE KD [mM] ±SE Bmax±SE KD [mM] ±SE Bmax±SE
ankBDn 0.3160.07 91.766.9 0.4360.05 2956261205 0.3460.09 3.660.4
SSSA .5- .5- .5-
WLSA 0.7160.34 76.5617.5 0.760.17 2528462553 0.7860.3 6.761.5
CLSC .11 0 6 . 9 631.2 0.8160.06 230166714 .1 6.560.8
WSSA 1.1460.24 73.468.8 .2 7010167493 .1 4.560.9
Ala8 .25 4 . 3 617.2 .2 4620963146 .2 8.262.0
SSSW .21 0 5 . 6 638.2 1.0360.17 3947963136 .2 6.861.1
ankBDnD 1638–
1767
0.5360.06 111.363.9 0.8560.09 3512161544 0.7160.3 4.460.8
doi:10.1371/journal.pone.0021538.t001
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hemoglobin, which was used as a carrier protein to stabilize the
recombinant proteins against precipitation. Also, some release of
erythrocyte spectrin (Fig. S3) during the resealing incubation was
observed in the presence of ankBDn but was not observed during
resealing in the presence of mutant proteins (Fig. S3).
Effect of ankBDn and its mutants on membrane skeleton
of transiently transfected HeLa cells
In recent studies by Chorzalska et al. [35] it appeared that the
spectrin-based skeleton aggregation inHeLacells correlated with the
presence of the N-terminal part of the ankBDn molecule. Moreover,
the co-aggregation of overexpressed ankBDn-conjugated construct
Figure 5. Inhibition assays and binding of ankSBD to ankBDn and its mutants. A) Inhibition of spectrin-PE/PC liposome binding by ankBDn
and its mutants. Fluorescently labeled erythrocyte spectrin (50 nM) was incubated with FAT PE/PC liposomes in the test buffer (see Materials and
Methods) at room temperature in the absence (100% binding) or presence of the indicated concentrations of recombinant proteins. B) Inhibition of
binding of ankBDn and its mutants to PE/PC monolayers by ankSBD. Recombinant ankBDn or its mutants were preincubated in appropriate
proportions with the recombinant ankSBD to obtain the indicated concentrations of ankyrin protein and concentrations of spectrin proteins inducing
the Dp changes below the plateau value. The data points represent average values of three independent experiments with an average
variation,10%. C) Binding of ankSBD to ankBDn and its mutants. Data obtained by EIA assay indicate similar affinities of all studied proteins for
binding ankSBD. KD values were in the range 27–55 nM. D) Pelleting assay results of inhibition of binding of ankBDn and its mutants to PE/PC
liposomes by ankSBD. Recombinant, fluorescently labeled ankBDn or its mutants were preincubated with FAT PE/PC liposomes at room temperature
in the absence (100% binding) or presence of the recombinant ankSBD at indicated concentrations. E) EIA results of inhibition of binding of ankBDn
and its mutants to PE/PC liposomes by ankSBD.
doi:10.1371/journal.pone.0021538.g005
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transmembrane proteins that are known to interact with membrane
skeletal structures via ankyrin, such as Na
+/K
+ATP-ase, L1 CAM
and IP3 receptor protein. However, co-aggregation of ankBDn did
not affect the actin skeleton or distribution of cadherins [35]. The
effects on cells were consistent with the postulate that aggregates
were connected to the membrane via ankyrin. In this study we tested
the effect of mutations in ankBDn on its ability to affect the
morphology of spectrin-based skeletal structures of HeLa cells. We
observed co-distribution of ankBDn or its mutants, SSSA and
CLSC, with Na
+/K
+ATP-ase, which indicates that our observations
pertain to the same events observed in our previous analysis of the
truncated mutants [28,35].
HeLa cells were transfected with the reporter vector pEGFP-C1,
carrying the subcloned wild-type ankBDn or its mutants. Empty
pEGFP-C1 reporter plasmid was used as a control. Overexpression
of the ankBDn-GFP construct resulted in its aggregation, which can
be seen as a punctate pattern. The presence of spectrin in the
aggregates was revealed with anti-spectrin antibodies depleted of
activity for ankBDn (data not shown, [28]). The co-distribution of
Na
+/K
+ATP-ase and ankBDn aggregates is obvious in cells
overexpressing wild-type ankBDn and less obvious in cells
overexpressing CLSC mutant. Cells overexpressing the SSSA-
GFP construct and control cells were indistinguishable (Fig. 8).
We also assessed possible endosomal localization of aggregates by
immunostaining with anti-EEA1 antibodies. We found that there
was no co-localization between ankBDn-GFP-spectrin aggregates
and endosomes (Fig. S4A). Finally, we performed western blot
analysis of transfected cells, which showed that GFP-fusion proteins
remained intact in HeLa cells, i.e. no substantial proteolysis was
observed (Fig. S4B).
In conclusion, these experiments on red blood cells and
transiently transfected HeLa cells showed that introduction of
recombinant ankBDn into those cells resulted in significant changes
in their morphology, and in formation of aggregates of spectrin-
based skeleton and the overexpressed protein, while introduction of
recombinant proteins with substitutions of the four residues in the
PE/PC-binding element failed to induce these changes. This
supports the idea that lipid-binding properties of ankBDn are of
physiological importance.
Figure 6. Model of ankBDn implementing 310 helix in N-terminus of helix 14C. A) ‘‘Closed’’ structure of ankBDn. B) The model of the ‘‘open’’
conformation of ankBDn which is detected upon lipid binding. Table shows distances between pairs of a carbons between proximal amino acid
residues in the energy-minimized model of spectrin repeat (ankBD) in the presence of PE:PC liposomes. Amino acid residues responsible for lipid
binding (W1771, L1775, M1778, W1779) are marked in green; those marked in violet are residues engaged in ankyrin binding located in close
proximity of lipid-binding site. The 310 helix element is marked in yellow, helix 14A is marked in red, helix 14B is marked in orange.
doi:10.1371/journal.pone.0021538.g006
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Our previous studies on interactions of spectrin with lipids
revealed PE/PC-binding activity of b-spectrin. A key feature of
this interaction was its sensitivity to inhibition by purified ankyrin
so the disposition of the PE/PC-binding site within the ankyrin-
binding domain was possible. Further studies defined a region in
the N-terminal part of the ankyrin-binding domain of the b-
spectrin involved in PE/PC binding [18]. In the next step of our
research, presented in this work, we identified key amino acid
residues responsible for lipid binding. Our approach was based on
the construction of several site-directed mutants of ankBDn with
different combinations of substitutions within the lipid-binding site
of this domain. The aim was to introduce mutations that would
perturb the hydrophobic surface in helix 14C, which appeared to
be well positioned to contact the bilayer (Fig. 1B, Fig. S1).
Our experiments showed that much of the PE/PC-binding
property of ankBDn is confined within 12 spectrin amino acid
residues (1768–1779). This interpretation is derived largely from
the observation that, compared to ankBDn, binding to the
monolayers by the quadruple mutant, SSSA, was markedly
decreased and that the other constructs carrying mutations within
the same region exhibited reduced abilities to bind lipid mono-
and bilayers. The combined results obtained from various lipid-
binding assays reveal that PE/PC-binding activity resides within
helix 14C of b-spectrin. Furthermore, the residues W1771, L1775,
M1778, and W1779 form a hydrophobic surface on one side of the
helix, which is involved in lipid/PE/PC binding. Any mutation of
the hydrophobic surface in helix 14C formed by these four
proximal residues led to a decrease in lipid-binding affinity.
Moreover, the lipid-binding affinity was inversely related to the
number of replacements of hydrophobic residues in this region of
the molecule, i.e. KD ankBDn,2 mutations,3 mutations,4
mutations. To quench PE/PC-binding activity all four residues
should be replaced in the recombinant ankBDn. We also
measured ankyrin sensitivity of ankBDn and its mutants. The fact
that residual binding of the quadruple mutant, SSSA, to the PE/
PC monolayer was insensitive to inhibition by ankyrin, coupled
with the fact that ankyrin inhibited about 80% of ankBDn binding,
suggested that the residual 20% of ankBDn binding is determined
by residues that are not involved in this lipid-binding site [6]. The
results of the EIA showed that all studied proteins had similar, high
affinity for ankSBD, indicating that binding to ankSBD is
unaffected by the introduced substitutions. We now conclude that
the minimal ankyrin-dependent, PE/PC-binding motif in eryth-
rocyte spectrin is 1771WXXXLXXMW1779.
A closer look at the crystal structure of the 14
th segment of
spectrin shows that the lipid-binding residues are buried between
Figure 7. The effect of resealing erythrocyte ghosts in the presence of ankBDn and its mutants. Hemoglobin (,1 mg/ml) or bacterially
expressed and purified ankBDn and its mutants, CLSC and SSSA (,1 mg/ml), were present in the resealing buffer. Resealed erythrocyte ghosts were
labeled with DID. Ghosts loaded with wild-type ankBDn show the most extensive shape change while those loaded with SSSA mutant resemble
control ghosts loaded with hemoglobin. For details see Materials and Methods. Scale bars: 10 mm.
doi:10.1371/journal.pone.0021538.g007
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state for interaction with the bilayer. To explore the possibility of a
structural arrangement of the PE-binding site we attempted to
built a model of the lipid-bound ankBDn. The model was based on
X-ray crystal structures of the b-spectrin lipid-free state but
incorporated restraints from site-directed spin labeling data
collected in the presence of PE/PC [19,22]. The mentioned
EPR studies were performed in solution and measured changes in
distance between site-directed spin labeled residues on helices of
the 14
th spectrin segment upon lipid binding. The distance
between the spin centers located in helix A and C was larger than
25 A ˚ [22], which suggested an interesting possibility for a mode of
interaction of ankBDn with the lipid bilayer, in which the helices
of the spectrin 14
th repeat partially separate from each other when
interacting with lipids. The solution state model also includes an
SDSL-based 310 helical element between residues 1764–1773 and
an unstructured conformation N-terminal to helix C.
Based on the EPR restraints, binding of PE/PC mono- and
bilayers by ankBDn is predicted to result in an ‘‘open’’ structure
with an exposed lipid-binding surface. Using the three distances
measured between proximal pairs of residues and assuming no
major changes in secondary structure of ankBDn, the membrane
Figure 8. Transient overexpression of ankBDn and mutants in HeLa cells. A) Overexpression of GFP-conjugated constructs; B)
Immunofluorescent staining with anti-Na
+/K
+-ATPase antibodies; C) Overlay. Distribution pattern of Na
+/K
+-ATPase is changed in cells transiently
overexpressing ankBDn and CLSC constructs. This is especially visible in cells overexpressing ankBDn, where GFP constructs colocalize with Na
+/K+-
ATPase. GFP plasmid was used as control. Scale bars: 20 mm.
doi:10.1371/journal.pone.0021538.g008
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expose the N-terminal part of helix 14C which spans the lipid-
binding site. This interaction site is no longer sterically restricted,
and would be free to interact with membrane phospholipids
through exposed hydrophobic and basic residues.
A similar mechanism was also proposed for the interaction of
dystrophin rod domains with anionic phospholipids as well as for
other proteins with tryptophan residues engaged in lipid-binding
activity [11,36]. Using the above-mentioned results of our previous
structural work we explored the possibility of structural arrange-
ment of the PE/PC-binding site. A model of ankBDn based on
crystal structures combined with the results of SDSL studies was
constructed (Fig. 6). The EPR spin-spin distance measurements
showed a possibility of the presence of 310 helix in the N-terminal
part of helix C of the 14
th segment of spectrin [19,22]. Although
this is a comparatively minor change to the crystal structure, it
presents some interesting features. As shown in Fig. 6, W1771
shifts outside the triple helical bundle when the 310 helix is
modeled. This residue could work as an initial point of attachment
of the protein to the lipid bilayer. Also the position of other
hydrophobic residues shown to be engaged in lipid binding,
including L1775, M1778 and W1779, further supports our
proposed mechanism as they form a compact hydrophobic patch.
Finally, our EPR-based model is an extrapolation from the static
crystal structure, and takes into account the conformational
flexibility in the N-terminal region of helix C in solution [37,38].
Although the model presented here explains the accessibility of
the lipid-binding site, its ankyrin sensitivity still remains to be
addressed. The recently published crystal structure of the spectrin-
ankyrin complex [20,21,32,33] sheds new light on the role of
ankyrin in the lipid-binding mechanism. Hydrophilic residues
from region 1770–1781 of the 14C helix (E1770, D1773, E1777,
D1781) as well as E1710 from the 14A helix were reported as
residues forming an ankyrin-binding interface on spectrin
[20,21,32,33]. These residues are in close proximity to the lipid-
binding site as defined by four hydrophobic residues: W1771,
L1775, M1778, and W1779. This proximity may provide an
answer to the question about the inhibitory effect of ankyrin on
lipid binding. We suggest that the ability of ankyrin to inhibit
ankBDn lipid binding is probably a result of steric interference by
ankyrin, which is caused by binding the E1710 residue which
blocks the ‘‘opening’’ of the triple helical bundle. This residue is
located close to the lipid-binding site, on helix 14A, and ankyrin
may prevent movement of this helix, which seems essential for PE
binding. The fact that the truncated mutant ankBDnD1638–1767,
which has the full lipid-binding site but lacks helices 14 A/B, is
basically insensitive to ankyrin seems to positively verify the
aforementioned hypothesis.
It is generally accepted that the major attachment site of spectrin
to the membrane occurs through the interaction with ankyrin. To
assessthe potentialphysiologicalrole ofthelipid-bindingdomainwe
designed experiments to test the interactions in the systems that
mimic the in vivo environment. Detailed experiments on truncated
mutants havebeen recently published[35],sohere onlyexamplesof
results of experiments performed on resealed erythrocyte ghosts and
HeLa cells transfected with constructs containing ‘‘wild-type’’ or
selected ankBDn mutants are presented. Surprisingly, although
ankBDn and its mutant show similar binding capacities (KD and
Bmax) for ankyrin (Fig. 5C), the deformation of resealed ghosts was
directly dependent on the potential of these constructs to bind PE/
PC (Fig. 7). The occurrence of dramatic changes in morphology of
erythrocyte ghosts resealed in the presence of ankBDn, and their
lack in the presence of SSSA, suggested the importance of the
mutated residues in maintaining mechanical properties of the
membrane and in maintaining the biconcave shape of erythrocytes.
These data support the data of Chorzalska et al. [35], who showed
that truncated mutants of ankBDn with greatly decreased lipid-
binding activity also failed to impose changes on ghost membranes,
and showed that barrier properties of erythrocyte ghosts resealed in
the presence of ankBDn were reduced. In a different experiment,
HeLa cells overexpressing ankBDn presented a punctate pattern
and displacement of spectrin associated with changes of distribution
of the integral membrane protein, Na
+/K
+ATPase. On the other
hand, overexpression of triple or quadruple mutants produced few,
if any, changesin comparison to controlcells (Fig. 8).These changes
cannot be attributed to ankyrin binding, but rather highlight the
importance of lipid-binding properties of the ankyrin-binding
domain, as demonstrated by the partial or complete loss of lipid
binding in the CLSC and SSSA mutants, respectively.
Previous work by Bennett et al. [39] showed that transfection of
intestinal caco-2 cells by the ankyrin-binding domain of bG-spectrin
leads to loss and displacement of endogenous spectrin and to
occurrence of a punctate pattern in cells. Here we observe similar
aggregates of overexpressed ankBDn but not of its mutants, that
have decreased lipid-binding properties. Moreover, co-localization
with Na
+/K
+-ATPase and presence of spectrin in aggregates of
ankBDn-GFP suggest that the spectrin-ankyrin-Na
+/K
+-ATPase
complex remains intact in contrast to the effect of expression of the
spectrin-binding domain of ankyrin, which extensively disrupts the
structure of the spectrin-based skeleton [31]. Altogether, these data
reveal that PE/PC binding of spectrin may be of more importance
for cellular homeostasis than previously thought.
Keeping in mind that each spectrin tetramer has two ankyrin-
binding domains and that in the erythrocyte membrane the
number of ankyrin molecules is equal to the number of spectrin
tetramers, the number of sites unoccupied by ankyrin is high.
These unoccupied sites may be bound to PE/PC-rich domains.
We speculate that overexpression of ankBDn, or its introduction
into erythrocyte ghosts, induces detachment of spectrin from the
lipid-binding sites and consequently permits its aggregation or
release. The ability of recombinant ankBDn to compete with
spectrin for liposomes under in vitro conditions, and the absence of
changes in cells with overexpressed/resealed SSSA mutant (which
lacks lipid-binding activity), supports this hypothesis.
We proposed previously that localization and ankyrin sensitivity
of spectrin-PE/PC binding provides a support function of this site
in ankyrin deficiencies [14]. In addition to the data provided in the
present work, two further examples should be mentioned. In
mouse erythrocytes with ankyrin deficiency, spectrin-based
skeleton was still normally formed [24]. In a different work, Das
et al. [40] showed that loss of the ankyrin-binding site in Drosophila
melanogaster b-spectrin had only a mild effect either on the
phenotype or on spectrin targeting to the membrane. Our results
suggest that loss of the ankyrin-binding site may be compensated
for by the presence of a PE-rich lipid-binding site that was still
present in Drosophila b-spectrin. This part of the ankyrin-binding
domain is one of the fragments among b-spectrin chains highly
conserved in evolution (Fig. S5).
In conclusion, our data support the hypothesis that lipid binding
by ankBDn is an important physiological feature of spectrin, which
plays a role in maintaining the properties of membrane and
membrane skeleton.
Materials and Methods
Constructs
We used a pRSET C expression vector carrying an ankyrin-
binding domain [18] in mutagenesis PCR reactions. Constructs
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residues and mutations were introduced in the region 1768–1786.
The following mutants were obtained by using Stratagene
QuikChange Site-Directed Mutagenesis Kit: MutSSK (L1782S,
L1785S, I1786K); MutSSD (L1782S, L1785S, I1786D); MutSSS
(L1782S, L1785S, I1786S); WLSA (M1778S, W1779A); WSSA
(L1775S, M1778S, W1779A); SSSA (W1771S, L1775S, M1778S,
W1779A); SSSW (W1771S, L1775S, M1778S); CLSC (W1771C,
M1778S, W1779C); and Ala8 (alanines at all positions from
residues 1768 to 1775). For expression of ankSBD protein we used
a previously obtained construct [31]. The constructs were
maintained in Escherichia coli strain, XL1Blue. All mutated
constructs were sequenced to verify mutations. Mutated spectrin
fragment proteins were expressed in BL21(DE3)pLysS cells.
Isopropyl b-D-thiogalactoside (100 mM) was used as an inducer
for 3 h at 37uC. Cells were lysed and proteins were extracted with
8 M urea and 100 mM NaCl in 20 mM Tris-HCl, pH 8.0, and
purified by immobilized Co
2+-affinity chromatography (Clontech).
Protein concentration was measured as described before [28]. The
purity of His-tagged proteins was assessed on Coomassie Blue-
stained SDS/PAGE (10%) gels (Fig. 2A).
Circular dichroism
Circular dichroism (CD) measurements were performed on a
JASCO J-715CD spectrometer as described previously [18].
Helical content was calculated from values of the amide np*
transition at 222 nm ([h222]), using a value of –36000 de-
grees?cm
2?dmol
21 to represent 100% a helical content [41].
Monolayer experiments
Monolayer measurements were performed by the Wilhelmy
technique, using a Teflon trough (surface area 24 cm
2) and a
Nima tensiometer (NimaTechnology, Coventry, UK), at room
temperature (21uC). Changes in surface pressure were measured
after addition of protein into the subphase and are presented as
Dp. The measurements were taken after 25 min following the
addition of the protein solution. For inhibition of lipid–protein
interactions by ankyrin, expressed spectrin polypeptides were
dialyzed against subphase buffer (5 mM Tris/HCl, pH 7.5,
0.5 mM EDTA, 150 mM NaCl, 0.5 mM dithiothreitol and
1 mM NaN3) and preincubated for 30 min at room temperature
with purified recombinant spectrin-binding domain of ankyrin
[31] at the desired polypeptide/ankyrin molar ratios, and were
then injected into the subphase [17]. Curves were fitted according
to the equation: B=Bmin+(B0-Bmin)/(1+10‘(Free-LogEC50)); B0 –
binding when competitor concentration=0; Bmin – minimal
binding level.
Liposome-binding assays
Fluorescent labeling of proteins. Purified as described
previously [15] erythrocyte spectrin and the expressed spectrin
fragments were fluorescently labeled using tetramethylrhodamine-5-
maleimide (Sigma Aldrich) according to the manufacturer’s
directions. Labeling efficiency, determined using a molar extinction
coefficient of rhodamine of 80,000 at 543 nm, was ,80%.
FRET-based assay. For FRET-based assay proteins were
labeled as follows: 36 ml of 22.5 mM tetramethylrhodamine
isothiocyanate (Molecular Probes) in DMSO was added to 1 ml of
protein solution (,1 mg/ml) in carbonate buffer, pH 9.2, in 5 ml
portions upon stirring. The reaction was carried out overnight at 4uC
in the dark. The unreacted label was quenched by adding Tris-HCl,
pH 8.5, to a concentration of 50 mM and sucrose to 0.5 M, and the
resulting mixture was dialyzed overnight to the ‘‘assay buffer’’
(20 mM Tris, pH 7.5, 150 mM NaCl). The labeling efficiency was
,80%.PE/PCliposomeslabeledwithNBD-PEataconcentrationof
0.5 mol% were prepared by hydration with the assay buffer. Next,
the lipid vesicles were calibrated by extrusion through a 100-nm pore
filter. Proteins labeled with TRITC were incubated with liposomes in
the assay buffer for 30 min at room temperature (21uC). After
incubation, NBD fluorescence was measured. KD (equilibrium
dissociation constant) and maximal binding capacity (Bmax)v a l u e s
were calculated according to the equation B=(Bmax * Free)/
(KD+Free) by using non-linear regression.
Electrochemiluminescence immunoassay. The EIA
experiments were performed according to the manufacturer’s
protocol (Meso Scale Discovery, MSD
H) based on the sandwich
immunoassay which utilizes electrochemiluminescence to measure
protein levels [42]. Briefly, liposomes were passively adsorbed on the
electrode surface (1 h, 23uC), and the residual sites on the surface
were blocked with 0.1% DB-blocker (1 h, 23uC). The surface was
then washed three times with 20 mM TRIS-HCl, 150 mM NaCl
and solutions containing the desired concentrations of proteins were
added to each well. Binding was carried out for 2 h at 23uC. Wells
were then washed and a solution of primary antibody (Qiagen)
against the His-Tag sequence was applied (1 mg/ml, 23uC, 1 h). The
wells were again washed, and secondary antibody (goat anti-mouse-
STAG) was added (1 mg/ml, 23uC, 1 h). The wells were washed and
reading buffer was added (MSD surfactant-free reading buffer). The
background was determined from binding of both primary and
secondary antibodies to liposomes. Data were acquired on a
SECTOR Imager 6000. The recorded data were analyzed using
GraphPad Prism 5.0 software using one site-specific binding
algorithm. To measure the interactions between ankBDn and its
mutants with the spectrin-binding domain (ankSBD) of ankyrin a
previously published protocol was used [34]. KD (equilibrium
dissociation constant) and maximal binding capacity (Bmax)v a l u e s
were calculated according to the equation B=Bmax *F r e e /
(Free+KD)+nonspecific binding. In the inhibition assay, the
equation B=(B0-Bmin)* exp(-Free *Free)+Bmin wasusedtofitcurves.
Pelleting assay. FAT liposomes were prepared by using
20 mM Tris, pH 7.5, containing 150 mM NaCl, and 20%
dextran T-200000. The liposome suspension was diluted with
the above buffer without dextran (assay buffer) and centrifuged at
30 000 g to remove small vesicles and untrapped dextran.
Fluorescently labeled proteins were incubated with FAT
liposomes in assay buffer for 30 min at room temperature
(21uC). After incubation, the samples were centrifuged at
30 000 g for 20 min. The liposome pellets were dissolved in 1%
(w/v) SDS for 10 min. Fluorescence measurements were
performed using a Cary Eclipse Varian Spectrofluorimeter. The
excitation and emission wavelengths for tetramethylrhodamine-
labeled proteins were 541 and 575 nm respectively. Competition
experiments were performed in the presence of an excess of
unlabeled recombinant ankyrin-binding domain and its mutants,
which were added to the samples with the liposomes and labeled
spectrin. KD (equilibrium dissociation constant) and maximal
binding capacity (Bmax) values were calculated according to the
equation B=(Bmax * Free)/(KD+Free) by using non-linear
regression. In the inhibition assay, the equation B=(B0–Bmin)*
exp(-Free * Free)+Bmin was used to fit curves.
Preparation of resealed ghosts
Fresh blood samples were collected from healthy human
volunteers (upon their informed, written consent) using anti-
coagulant (0.8% citric acid monohydrate, 2.2% trisodium citrate,
2.2% glucose). Red cells were washed three times with 10 mM
Tris-HCl buffer (pH 7.4) containing 120 mM KCl. Intact cells
were lysed in ice-cold lysis buffer containing 0.6 mM MgATP in
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centrifuged (15 000 g, 15 min, 4uC) and washed in the same
buffer until pale pink. The ghosts were resuspended in resealing
buffer (150 mM KCl, 1.6 mM MgCl2, 1 mM DTT, 0.6 mM
MgATP, pH 7.4), and incubated for 60 min, at 37uC in the
presence or absence of hemoglobin or recombinant ankBDn or its
mutants (final concentration 1 mg/ml). After resealing, the
suspension was centrifuged (10 000 g, 5 min, 4uC), and pellets
and supernatants were collected for further analysis. Resealed
ghosts were stained with lipophilic dye, Vybrant
H DiD (Molecular
Probes), according to the manufacturer’s instructions. The consent
of the Ethics Committee was not necessary as the blood samples
were taken in the clinical laboratory and used only for simple
experiments on erythrocytes and no patient treatment or genetic
analysis was involved.
Transfection of HeLa cell culture
Transient expression of fluorescent recombinant proteins
in HeLa cell culture. PCR products coding for ankBDn and its
mutants (SSSA and CLSC) were cloned into pEGFP-C1
(Clontech). GFP was located at the N-termini of the constructs.
HeLa cells (human epithelial carcinoma cell line) were transiently
transfected in 24-well plates as described by Bok et al. [28]. HeLa
cell line was obtained from Ludwik Hirszfeld Institute of
Immunology and Experimental Therapy of Polish Academy of
Sciences in Wrocław.
Immunostaining. Cells were washed several times with PBS
and fixed with paraformaldehyde (2%) in PBS, permeabilized with
0.1% Triton X-100 in PBS, and washed again with PBS.
Thereafter the cells were blocked for 15 min with 100% FBS
and incubated for 1 h 45 min with primary antibodies (polyclonal
rabbit anti-human Na
+/K
+ ATPase a1, Santa Cruz
Biotechnology, 2 mg/ml and monoclonal mouse anti-human
EEA1, BD Biosciences, 250 mg/ml) at room temperature. Cells
were then washed three times with PBS. As a secondary antibody,
TRITC-labeled goat anti-rabbit IgG (Jackson Immuno Research,
1:100) or Cy-5 labeled donkey anti-mouse (BD Biosciences, 1:100)
was used. Cells were examined by confocal microscopy using a
Zeiss LSM 510 Meta microscope and Plan Apo 63x/1.4 lens
objective.
Western blot analysis. HeLa cells were collected 24 h after
transfection and subjected to SDS-PAGE. Separated proteins were
transferred to nitrocellulose membranes (Whatman). Antibodies
and dilutions used included anti-ankBDn polyclonal antibodies
prepared in our laboratory (1:1000), and secondary antibody
conjugated with alkaline phosphatase (Jackson ImmunoResearch)
(1:2500).
Structure prediction and analysis
The spectrin model was built using homology modeling within
Modeller 9v6 [43] from residues 1584 to 1889 choosing the
structures of b-spectrin (PDB ID 3 kbt and 3edv) as templates.
Residues 1764 to 1773 were definedas a 310 helix [19] and modeled
from an ab initio template of the sequence drawn in HyperChem.
The model of the spectrin structure was subjected to rigid
minimization within Xplor-NIH [44] and restrained by the EPR-
derived restraints [22] which had been collected in the presence of
PE/PC liposomes. Distance restraints were implemented between
Ca carbons of the residues. The three EPR-based distances used
for the calculation were between residues 1699 and 1768 (20.5+/
-2.5 A ˚), residues 1710 and 1779 (,25 A ˚), and residues 1750 and
1771 (19.4+/-2.5 A ˚).
Regions including residues 1584 to 1714, 1722 to 1760, and
1764 to 1889 were kept rigid during the minimization, allowing
each helix to move freely and satisfy the distance restraints.
Mutant protein models used for analysis of hydrophobicity were
modeled using the non-commercially available program 3D-
Jigsaw from the website: http://bmm.cancerresearchuk.org/
,3djigsaw/ [45] and visualized by Yasara and 3D-mol open-
source programs. The PDB ID code of the template structure is
3edu.
Supporting Information
Figure S1 Hydrophobic plot of 1768–1805 region. A)
WLSA, B) MutSSS, C) WSSA, D) SSSW , E) CLSC, F) Ala8,
Deep red, hydrophobic, deep blue, hydrophilic; substitutions are
marked.
(TIF)
Figure S2 Binding of fluorescently labeled recombinant
proteins by FAT PE/PC liposomes. Amount of bound
protein was calculated according to standard curve obtained for
fluorescently labeled proteins. A) Comparison between ankBDn
and quadruple mutant SSSA, using thermally denatured ankBDn
as negative control. B) Binding curves obtained for the remaining
mutants.
(TIF)
Figure S3 SDS-PAGE analysis of pellets and superna-
tants collected after resealing erythrocyte ghosts. P,
pellet; S, supernatant. Arrow indicates resealed proteins. Similar
amount of proteins was resealed in all cases and resealing
efficiency was estimated to be 50–60%. The same volumes of
pellet and supernatants were loaded onto the gel. Released
spectrin is observed in supernatant collected from ghosts resealed
with ankBDn. 10% polyacrylamide gel stained with Coomassie
Blue.
(TIF)
Figure S4 Analysis of observed aggregates. A) Cells
transfected with pEGFP reported plasmid (first row) and with
ankBDn-GFP construct (second row) stained with anti-human EEA1
antibodies. No colocalization between aggregates and endosomes is
observed. B) Western blot analysis with anti-ankBDn antibodies of
lysed HeLa cells transfected with ankBDn-GFP or SSSA-GFP
constructs. No substantial proteolysis is observed. Scale bars: 20 ı `m.
(TIF)
Figure S5 Alignment of known b-spectrin sequences
corresponding to ankyrin-binding domain. The box
outlined in red indicates the 38 amino acid region encompassing
the putative lipid-binding site. Arrows mark residues that were
substituted in various ankBDn mutants.
(TIF)
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